[et_pb_section fb_built=”1″ _builder_version=”4.6.1″ _module_preset=”default”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.6.1″ _module_preset=”default”][et_pb_column type=”1_2″ _builder_version=”4.6.1″ _module_preset=”default”][et_pb_video src=”https://vimeo.com/475044775″ _builder_version=”4.6.1″ _module_preset=”default”][/et_pb_video][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.6.1″ _module_preset=”default”][et_pb_text _builder_version=”4.6.1″ _module_preset=”default”]
Dr Roshni Kalachand describes the experience of opening CTRIAL-IE 18-01 The tBRCA study together with Cancer Trials Ireland
Dr Kalachand’s presentation is available here.
The study aims to assess whether it is feasible to routinely test all women with a newly diagnosed or a recurrent ovarian cancer for a mutation in the BRCA1 and BRCA2 genes when they present to the oncology clinic, using both tumour and blood samples. The study is now closed to accrual (i.e no longer recruiting) and patients on study are in Follow Up.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]